FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| п | | |
|---|--------------------------|-----------|
| | OMB Number: | 3235-0287 |
| | Estimated average burden | |
| ı | hours per response. | 0.5 |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person Salzmann Peter | | | 2. Issuer Name and Ticker or Trading Symbol Immunovant, Inc. [IMVT] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | | | |
|--|-------------------------|-------|---|---|---|---------------------------------|--|--|--|--|--|
| (Last) | (Last) (First) (Middle) | | 3. Date of Earliest Transaction (Month/Day/Year) 07/12/2023 | X | Officer (give title below) | 10% Owner Other (specify below) | | | | | |
| C/O IMMUNOVA | ANT, INC. | | | Chief Executive Officer | | | | | | | |
| 320 W 37TH STREET, 6TH FLOOR | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | | | |
| (Street) NEW YORK | NY | 10018 | | X | Form filed by One Reporting Form filed by More than One | | | | | | |
| | | | Rule 10b5-1(c) Transaction Indication | | | | | | | | |
| (City) | (State) | (Zip) | Check this box to indicate that a transaction was made pursuant to a contra affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | ct, instructi | on or written plan that is intended | to satisfy the | | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | tion Date, Transaction Code (Instr. | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | Securities | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership |
|---------------------------------|--|---|-------------------------------------|---|--|---------------|------------|------------------|---|-------------------------|
| | | | Code | v | Amount | (A) or (D) | Price | (Instr. 3 and 4) | | (Instr. 4) |
| Common Stock ⁽¹⁾ | 07/12/2023 | | S | | 3,233 | D | \$19.73(2) | 1,231,136 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| | 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3A. Deemed Execution Date, if any (Month/Day/Year) | Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | | Ownership Form: Direct (D) | Beneficial Ownership (Instr. 4) |
|--|--|---|---|-----------------------------------|---|--|-----|--|--------------------|--|-------------------------------------|---|------------------------------|----------------------------------|---------------------------------------|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | Transaction(s) (Instr. 4) | | |

Explanation of Responses:

- 1. On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 8,281 of these RSUs vested on July 1, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
- 2. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$19.39 \$20.12 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this

Remarks:

/s/ Eva Renee Barnett, attorney-infact for Peter Salzmann 07/13/2023

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.